Regenxbio (RGNX) Reports First Patient Dosing in Cohort 3 of Phase I/II Trial of RGX-121 for Treatment of MPS II (Hunter Syndrome)
Go back to Regenxbio (RGNX) Reports First Patient Dosing in Cohort 3 of Phase I/II Trial of RGX-121 for Treatment of MPS II (Hunter Syndrome)| Jennison Natural Resources Fund Class B (NASDAQ: RGNX) | Delayed: 16.06 +0.02 (0.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.04 | 52 Week High | $25.00 | |||
| Open | $15.80 | 52 Week Low | $7.07 | |||
| Day High | $16.16 | P/E | N/A | |||
| Day Low | $15.29 | EPS | $0.00 | |||
| Volume | 604,238 | |||||
